Geode Capital Management LLC Has $48.40 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Geode Capital Management LLC boosted its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 11.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 823,839 shares of the company's stock after acquiring an additional 82,978 shares during the quarter. Geode Capital Management LLC owned 1.83% of Apogee Therapeutics worth $48,401,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in shares of Apogee Therapeutics by 35.7% in the third quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company's stock valued at $282,798,000 after purchasing an additional 1,267,451 shares during the last quarter. Waypoint Capital Advisors LLC bought a new stake in Apogee Therapeutics during the 3rd quarter worth about $36,835,000. Janus Henderson Group PLC grew its holdings in shares of Apogee Therapeutics by 4,018.9% in the 3rd quarter. Janus Henderson Group PLC now owns 469,557 shares of the company's stock valued at $27,586,000 after acquiring an additional 458,157 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Apogee Therapeutics by 162.7% during the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company's stock worth $41,545,000 after acquiring an additional 438,036 shares in the last quarter. Finally, Barclays PLC boosted its position in Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after purchasing an additional 287,243 shares during the last quarter. Institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Trading Down 0.4 %

APGE stock traded down $0.18 during mid-day trading on Tuesday, hitting $47.32. 168,076 shares of the company were exchanged, compared to its average volume of 501,633. Apogee Therapeutics, Inc. has a 1-year low of $27.05 and a 1-year high of $72.29. The stock has a market capitalization of $2.13 billion, a PE ratio of -19.55 and a beta of 2.33. The business has a 50 day simple moving average of $50.28 and a 200-day simple moving average of $48.44.

Insider Transactions at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 6,665 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $46.07, for a total value of $307,056.55. Following the completion of the sale, the insider now owns 260,798 shares of the company's stock, valued at approximately $12,014,963.86. The trade was a 2.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the company's stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the completion of the transaction, the chief executive officer now owns 1,354,487 shares in the company, valued at $76,162,804.01. This trade represents a 2.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 94,535 shares of company stock worth $5,133,635. Company insiders own 36.10% of the company's stock.

Wall Street Analyst Weigh In

APGE has been the topic of several recent analyst reports. Wedbush boosted their price target on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an "outperform" rating in a research report on Monday, December 2nd. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.